Cambridge, Massachussetts-based orphan oncology company ARIAD Pharmaceuticals has appointed Jennifer Herron as its new chief commercial officer.
She will succeed current CCO Martin Duvall, who will work closely with Herron as she takes up the role at the end of May.
Paris Panayiotopoulos, president and chief executive of ARIAD, said: “I am delighted that Jennifer will be joining ARIAD as our chief commercial officer.
“Jennifer is a proven leader with … experience across multiple therapeutic areas, specifically oncology, immunoscience and cardiovascular/metabolics, which I am confident will her serve her well in maximising the commercial opportunity for Iclusig and, if approved, brigatinib.”
Herron brings over 23 years of pharmaceutical experience to the firm, joining from Bristol-Myers Squibb where she most recently served as head of commercial transformation and operating model.
Prior to this, Herron held a number of senior roles at the firm including vice president for US immunology between 2014 and 2016, and general manager for its Puerto Rico and Caribbean operations from 2012 to 2014.
Herron has worked for Boehringer Mannheim Pharmaceuticals, GlaxoSmithKline/SmithKline Beecham and Novartis.
She said: “I am excited about this incredible opportunity at ARIAD.
“I look forward to working with the team to maximize the commercial performance of Iclusig, prepare for the potential US launch of brigatinib, and collaborate with R&D colleagues to further advance the pipeline.”